PATENT CLAIM ANALYSIS

Application Number: 15892140
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "001100"]

Abstract:
Provided herein are peptides comprising an amino acid sequence having at least about 85% sequence identity to RYRPRAPIIAVT (SEQ ID NO: 1). These cationic peptides inhibit PKM2 methylation and may be used in the treatment of breast cancer and other diseases or conditions in which PKM2 is overexpressed. Such PKM2 peptides may be delivered to cancer cells using pH sensitive unimolecular nanoparticles comprising anionic polymers.

Claim (Index 16):
The unimolecular nanoparticle of  claim 10  wherein\n the dendritic polymer is a PAMAM dendrimer having 3-4 generations and a molecular weight of about 5,000 to about 15,000 Da; \n the pH-sensitive linker is a cis-aconityl group; \n each anionic polymer has a polyasparagine backbone attached to an ethylene-amino-ethyleneamino-cis-aconityl or ethylene-amino-ethylamidoimidazole group or salt thereof and the ratio of the carboxyl groups to imidazole groups is from 1:1 to 5:1; and \n the molecular weight of the PEG is about 1,000 to about 15,000 Da.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 88.0
- Lexical Diversity: 1.24138
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15555482', '15551995', '13516511', '15563533', '15383454']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7385674195380244
- 35 USC 102 Novelty (BERT): 0.5113071305623786
- Combined Prediction Score: 0.7158413906404598
- Mean Citation Score: 200.830826
- Max Citation Score: 225.31363
- Similarity Product: 132.99193759454607

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test